DepoTech Starts Filing NDA For DepoCyt

2 December 1996

- DepoTech has begun the filing of its New Drug Application with the US Food and Drug Administration for its anticancer agent DepoCyt (sustained-release cytarabine) for patients with neoplastic meningitis arising from solid tumors. In a pivotal Phase III trial, DepoCyt demonstrated a higher complete response rate, a higher median survial and a longer time to disease progression compared to methotrexate (Marketletter October 28). In alliance with Chiron, Phase III trials will continue, with a Phase IV trial also underway in the USA and Canada. Chiron is conducting trials in Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight